Analyst Daniel Clark from Leerink Partners reiterated a Hold rating on Elanco Animal Health (ELAN – Research Report) and decreased the price target to $12.00 from $14.00.
Daniel Clark has given his Hold rating due to a combination of factors surrounding Elanco Animal Health’s current market position and future prospects. The company is in the process of launching new products in both the Pet Health and Farm Animal sectors, which are crucial for achieving targeted growth by 2025. However, despite the positive momentum in their cattle franchise and promising initial indicators for new product launches like Zenrelia and Credelio Quattro, there is insufficient evidence at this time to warrant a more optimistic outlook.
Furthermore, while the company’s increased innovation revenue target is encouraging, the lack of detailed information on the building blocks of this target adds a layer of uncertainty. The heavy investment in manufacturing, sales, and marketing, although necessary for future growth, currently exerts downward pressure on their financials. Consequently, the decision to maintain a Hold rating reflects a cautious approach, as the success of these strategic initiatives remains to be seen.
According to TipRanks, Clark is a 2-star analyst with an average return of 0.8% and a 50.00% success rate. Clark covers the Healthcare sector, focusing on stocks such as Zoetis, Idexx Laboratories, and Elanco Animal Health.
In another report released on February 25, Morgan Stanley also maintained a Hold rating on the stock with a $13.00 price target.
Questions or Comments about the article? Write to editor@tipranks.com